Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity was posted on October 28, 2019. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Canine Freeze Dried Plasma- Sole Source Notice

Closed
W81XWH-FY20-CFDP-Sole-SourceFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
Pre-Award Synopsis Texas Shield
Solicitation # DARPA-SN-27-07
The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.
Defense Advanced Research Projects Agcy

POSTED

4 days ago

DEADLINE

in 26 days
NAICS: 541714
New
Federal
Q--AMPLICON SEQUENCING SERVICES
Solicitation # 140G0226Q0047
Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.
Ofc Of Acquisition Grants-Denver

POSTED

4 days ago

DEADLINE

in 3 days

General Info

Agency

N/A

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Peter D. MitchellContract Specialist

Full Description

Show more
NOTICE OF INTENT TO AWARD A SOLE SOURCE The United States Army Medical Research Acquisition Activity (USAMRAA) intends to issue a Cost Plus Fixed Fee sole source contract under the authority of FAR 6.302-1 (a) (2) - Only One Responsible Source and No Other Services will Satisfy Agency Requirements, on or about 31 January 2020 to BodeVet, Inc., 9210 Corporate Blvd, Suite 310 Rockville, MD 20850, on behalf of the United States Army Medical Materiel Development Activity (USAMMDA). The Government has a requirement for the purpose of conducting a Phase 2/3 clinical trial that supports a treatment indication for hemorrhagic shock secondary to trauma, and associated dosing, for canine lyophilized platelets and canine lyophilized plasma (in combination and separately) as U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) products. BodeVet is uniquely positioned to execute the necessary development activities and is the only entity capable of adding a hemorrhagic shock indication to their StablePlate RXTM and StablePlasTM products. BodeVet is the regulatory sponsor of these products and there are no other known manufacturer producing both lyophilized canine plasma and platelets. Interested contractors may identify their interest and bona fide capability to fulfill this requirement, to include both lyophilized canine plasma and platelets. This notice of intent is not a request for competitive proposals. Interested parties who believe they can meet this requirement shall submit information about their capabilities no later than 10:00 AM EST, 13 NOVEMBER 2019. All questions and responses concerning this notice shall be emailed to Peter D. Mitchell at peter.d.mitchell8.civ@mail.mil. All information shall be furnished at no cost or obligation to the Government. No solicitation will be made available. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this proposed solicitation based upon responses to this notice is solely within the discretion of the Government. Telephone inquiries will not be accepted.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS